Genentech’s Gavreto scores US approval for RET thyroid cancer
Precision therapy is designed to selectively target RET alterations
Read More
Tag: Gavreto
Genentech’s Gavreto cleared for RET non-small cell lung cancer
The personalised cancer treatment has received conditional approval in the US
Read More
- Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
- European approval enables measles protection with CSL’s immunoglobulin Privigen
- JJP Biologics reports positive interim phase 1b data for nebaprubart
- Immunotherapy boost can spare more bladder cancer patients major surgery
- Deep Science Ventures and MDC partner to accelerate brain treatments
